Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Todos Medical Ltd TOMDF

Todos Medical Ltd is a Israel-based clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer. The Companys Total Biochemical Infrared Analysis (TBIA) platform, represents a method for cancer screening of solid tumors using peripheral blood spectroscopy analysis. The process involves observing the immune system’s response to tumor... see more

Recent & Breaking News (GREY:TOMDF)

Todos Medical, Ltd. Signs Non-Binding Memorandum of Understanding with Orot+ for Distribution Rights of its Breast Cancer Screening Tests in Romania and Austria

GlobeNewswire September 13, 2018

Todos Medical, Ltd. Appoints Herman Weiss, MD MBA as New Chief Executive Officer

GlobeNewswire July 31, 2018

Todos Medical reports on results of clinical trials for its blood test for breast cancer screening (TM - B1) conducted at Kaplan Hospital in Rehovot, Israel

GlobeNewswire March 22, 2018

Mr. David Ben Naim, CPA, MBA Joins Todos Medical as Chief Financial Officer

GlobeNewswire February 6, 2018

Todos Medical Appoints Dr. Meir Silver as Vice President of Clinical Research and Regulatory Affairs

PR Newswire August 29, 2017